Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial.

MLA

Woo, Janghee, et al. “Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial.” Cancer Prevention Research (Philadelphia, Pa.), vol. 17, no. 9, Sept. 2024, pp. 429–36. EBSCOhost, https://doi.org/10.1158/1940-6207.CAPR-23-0342.

APA

Woo, J., Zhai, T., Yang, F., Xu, H., Healey, M. L., Yates, D. P., Beste, M. T., & Steensma, D. P. (2024). Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial. Cancer Prevention Research (Philadelphia, Pa.), 17(9), 429–436. https://doi.org/10.1158/1940-6207.CAPR-23-0342

Chicago

Woo, Janghee, Tingting Zhai, Fang Yang, Huilei Xu, Margaret L Healey, Denise P Yates, Michael T Beste, and David P Steensma. 2024. “Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial.” Cancer Prevention Research (Philadelphia, Pa.) 17 (9): 429–36. doi:10.1158/1940-6207.CAPR-23-0342.